Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 9Breast Neoplasms 6Lymphoma, B-Cell, Marginal Zone 4Barrett Esophagus 4Lymphoma, Large B-Cell, Diffuse 3Inflammation 3Head and Neck Neoplasms 3Zollinger-Ellison Syndrome 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Lymphoma 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Stomach Ulcer 1Solid Tumours 1Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostate Cancer Patients 1Precancerous Gastric Lesions 1Pharmacokinetics of MDV3100 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Obesity 1Mouth Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 65Peripheral Blood Stem Cell Transplantation 37fludarabine phosphate 36Doxorubicin 31Etoposide 30Vincristine 29Whole-Body Irradiation 28Rituximab 26Prednisone 26Brentuximab Vedotin 26Mycophenolic Acid 25Filgrastim 22Cyclosporine 22Methotrexate 20Busulfan 19Cytarabine 18Radiotherapy 17Antilymphocyte Serum 16Tacrolimus 15Melphalan 15Carboplatin 14Ifosfamide 13Bortezomib 13Methylprednisolone 12Gemcitabine 11Flow Cytometry 10Lenalidomide 9Dexamethasone 9romidepsin 8Vorinostat 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × Omeprazole × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡